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Abstract: Background: Pharmacological treatment of obesity and glucose-insulin metabolism
disorders in children may be more difficult than in adults. Thus, we evaluate the effects of metformin
in comparison with metformin plus a polysaccharide complex (Policaptil Gel Retard®, PGR) on body
weight and metabolic parameters in obese children and adolescents with metabolic syndrome (MetS).
Patients and methods: We retrospectively collected 129 children and adolescents (67 girls, 62 boys;
median age 12.6 years) treated for a minimum of two years with metformin and low glycemic index
(LGI) diet. Of these, 71 patients were treated with metformin plus PGR after at least 12 months
of metformin alone. To minimize the confounding effect of the LGI on auxological and metabolic
parameters, the patients were compared with age-, sex-, and BMI-matched control group with obesity
and MetS (51 subjects; 24 males, 27 females) treated only with a LGI diet. Assessments included lipids,
glucose and insulin (fasting and after oral glucose tolerance test) concentrations. The Homeostatic
Model Assessment of Insulin Resistance (HOMA-IR), Matsuda, insulinogenic and disposition indices
were calculated. Results: Metformin treatment led to a significant reduction in BMI SDS (p < 0.0001),
with a significant difference in ∆BMI SDS between patients and controls (p < 0.0001). Moreover,
metformin treated patients showed a reduction in HOMA-IR (p < 0.0001), HbA1c levels (p < 0.0001)
and a significant increase in Matsuda index (p < 0.0001) in respect to the reduction discovered in
controls (p < 0.05). Moreover, in contrast to the group treated with metformin alone and controls,
patients treated with metformin plus PGR showed a further reduction in BMI SDS (p < 0.0001),
HOMA-IR (p < 0.0001), HbA1c (p < 0.0001), total, HDL and LDL cholesterol (p < 0.0001), as well as an
increase in Matsuda (p < 0.0001), disposition (p < 0.005) and insulinogenic (respectively, p < 0.05 and
p < 0.0001) indices. Conclusions: Metformin appears to show short-term efficacy in reducing BMI,
adiposity and glucose and insulin parameters in obese children and adolescents with MetS. However,
PGR added to metformin may be useful to potentiate weight loss and to improve glucose-insulin
metabolism and adiposity parameters in these patients.
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1. Introduction
Obesity is a multifactorial disease with a rapidly increasing prevalence in children and adolescents
and a significant impact on both physical and psychosocial health [1]. More than one third of children
and adolescents are reportedly at risk of being overweight or obese in Italy [2] and many other
European countries [3–5].
Concomitant with the global rise in pediatric obesity, there has been a significant increase
in the number of children and adolescents with clinical signs of insulin resistance [6,7], the main
pathophysiological event preceding metabolic syndrome abnormalities [6–9]. Furthermore, the
incidence of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes (T2DM) in
obese children and adolescents has risen alarmingly [6–9].
Lifestyle changes such as a healthy diet and regular physical activity have been proposed as
the gold standard of care in subjects with obesity, albeit with poor compliance and success [6–9].
However, given that insulin resistance is an important link between obesity and associated metabolic
abnormalities and cardiovascular risk, clinicians should be aware of high risk groups and the necessary
treatment approaches [6,7].
There is now a general consensus that the pharmacological treatment of T2DM or severe disorders
involving insulin secretion and action may be more difficult in children than in adults [10]. The first
problem is that most of the available medications have not been studied in children [10].
The American Diabetes Association and the Pediatric Endocrine Society recently prepared joint
guidelines for the treatment of T2DM in children [11,12]. Metformin, a biguanide agent that decreases
hepatic glucose production and increases peripheral insulin sensitivity, has been used in conjunction
with a lifestyle intervention program in T2DM obese adolescents with clinical insulin resistance to
achieve weight loss and improve insulin sensitivity [13]. As in adults, metformin remains the mainstay
of therapy (alongside diet and exercise) in T2DM children and adolescents, even if the treatment
should focus on lifestyle changes to achieve effective weight management [10].
In any case, metformin may be a useful adjuvant treatment in obese and/or insulin-resistant
children and adolescents, although its role in this setting is still unclear [14–16].
Nevertheless, although lifestyle changes may produce significant weight reduction in children
and adolescents, the long-term efficacy of lifestyle intervention programs on body mass index (BMI)
and related complications is questionable, given the high dropout and the frequent relapse into obesity
of these patients [17]. For this reason, adding a pharmacological agent to conventional treatment is
often considered in clinical practice.
Metformin must be taken with food. This can be a problem in children and adolescents, who
often find it difficult to manage their eating, potentially leading to hypoglycemia [18]. Metformin
may also be associated with gastrointestinal adverse events, commonly including abdominal pain and
diarrhea [19]. Although rare, lactic acidosis may also occur [20].
Policaptil Gel Retard® (PGR) is a complex of polysaccharide macromolecules that may reduce peak
blood glucose and insulin levels [21]. It may thus be able to reduce BMI, HbA1c levels, the frequency
of acanthosis nigricans and glucose metabolism abnormalities in obese children and adolescents with
severe hyperinsulinism, insulin resistance and a family history of T2DM and obesity [21].
The aim of this study was to retrospectively evaluate the effect of metformin and/or metformin
plus PGR in treating severe hyperinsulinism and insulin resistance in a large cohort of obese children
and adolescents with metabolic syndrome (MetS).
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2. Patients and Methods
This was a retrospective single center study. One hundred twenty-nine Caucasian obese patients
(67 females, 62 males; median age at study entry 12.6, range 8.1–14.3 years) with hyperinsulinism and
insulin resistance associated with MetS were studied at the Paediatric Endocrinology Unit at the Meyer
Children’s University Hospital of Florence, Italy.
Inclusion criteria were the presence of severe hyperinsulinism, insulin resistance and MetS and
age between 8.0 and 14.5 years at the first evaluation. Exclusion criteria were patients aged <8.0 years
or >14.5 years at the first evaluation, cognitive impairment, diagnosis of type 1 diabetes, existing
syndrome disorders with or without cognitive impairment, impaired renal or hepatic function,
malabsorption disorders, cancer, patients enrolled in a weight loss program at the first evaluation,
endocrine causes of obesity such as hypothyroidism or Cushing disease, and use of medications for
weight loss or any medication that could compromise the study evaluation such as topical or systemic
glucocorticoids, anticonvulsant therapy, growth hormone, sexual steroids or gonadotropin releasing
hormone analogues.
This study was conducted in compliance with the Declaration of Helsinki and European
Guidelines on Good Clinical Practice. Ethical approval (ethical code 122/2016) was obtained from
the Meyer Children’s University Hospital Ethics Committee. Written informed assent/consent was
obtained from all participants and their parents or guardians.
3. Study Design
One hundred twenty-nine patients recruited for severe obesity, hyperinsulinism and insulin
resistance associated with MetS were retrospectively evaluated. After the first evaluation, all
patients started metformin (T0) and they were followed up after 12 months (T1; median age 13.7,
range 9.1–15.4 years) and 24 months (T2; median age at study end 14.9, range 10.3–16.7 years). Because
of data demonstrating improvements in adiposity and gluco-insulinemic parameters with the use of
PGR in obese children and adolescents with family history of obesity and T2DM [21], we after the
initial 12 months of metformin treatment we recruited 71 patients also treated with PGR (Group A),
while 58 patients continued with metformin only (Group B). These patients were compared with a
age-, sex-, and BMI-matched control group with obesity and MetS (51 subjects; 24 males, 27 females;
median age at study entry 12.4, range 8.2–14.5 years) not taking a medication as a mean to reduce
weight and treated only with a low glycemic index (LGI) diet.
At the first evaluation (T0), the parents of the study participants also completed a previously
tested health questionnaire and a semi-structured quality-of-life questionnaire [19,20]. Information
on duration of pregnancy, birth weight, neonatal feeding and presence of diabetes gravidarum
during the pregnancy of the participants’ mothers and on diseases, hospital admissions and use
of medication was collected. Family history was also investigated, collecting data on hypertension,
obesity, hypercholesterolemia, cardiovascular disease (myocardial infarction, stroke, transient ischemic
attack, and peripheral arterial occlusions) and diabetes mellitus in first degree (parents) and second
degree (grandparents, brothers, sisters) family members. Complementary information was also
collected from the medical files. Nutrient diaries were logged for all subjects according to their medical
charts and through standardized interviews [19,20].
At T0, T1 and T2, we collected, when available, clinical and demographic data including height,
weight, BMI, waist (WC) and hip circumference (HC), waist–hip ratio (WHR), pubertal staging and
the time dedicated to outdoor physical activity, using a questionnaire commonly administered at the
medical evaluation in obese children in our hospital [21].
During the T0, T1 and T2 visits, an extensive physical examination was performed by the study
physicians. This included auscultation of the heart, lungs and abdomen and abdominal palpation.
Any abnormal findings were recorded. The skin was examined for acanthosis nigricans, striae rubra,
acne and, in girls, hirsutism.
Nutrients 2017, 9, 524 4 of 17
At T0 blood was taken for glycosylated hemoglobin (HbA1c), oral glucose tolerance test (OGTT),
renal profile, lipid profile (including total, HDL LDL cholesterol and triglycerides), full blood count,
IgA anti-tissue transglutaminase antibody (tTG) and total IgA levels. HbA1c, OGTT, renal profile,
lipid profile and full blood count were also repeated at T1 and T2.
Finally, in addition to the data obtained from telephone interviews, a questionnaire was completed
at T1 and T2 to assess any side effects that had occurred during the study. However, as per clinical
practice, all patients underwent a telephone interview every three months to monitor BMI changes
and any adverse events of treatments.
As for clinical practice in our Unit, because of research demonstrating improvements in adiposity
and gluco-insulinemic parameters [21], all patients with obesity and MetS were treated with a LGI
diet. Subjects were visited or interviewed every three months by a dietician (M.A.S.), for nine sessions
during the 24-month intervention period, to receive standardized instructions for healthy eating and
exercising. Counseling sessions included the child and at least one parent, when possible, according
the established practice. Each session lasted approximately 30 min and was based on a strategy
of increasing energy expenditure and modifying the dietary food intake using lifestyle behavioral
change to achieve long-lasting impact. The dietician completed a tracking form and progress note
after each counseling session to document patterns of dietary intake. Regarding the physical exercise,
we encourage children to do aerobic exercise, such as swimming, cycling, running, and dancing,
2–3 times per week.
3.1. Metformin Treatment
After the T0 evaluation results, in the daily practice, subject’s study medication dose was
progressively increased according to a prespecified algorithm: in Weeks 1 and 2, participants took
one tablet (500 mg) daily; thereafter, the dosage was increased by 500 mg/day every seven days to a
maximum dose of 1500 mg/day (three tablets). Treatment was administered during meals (to minimize
gastrointestinal side effects and the risk of hypoglycemia). In the event that the participant developed
gastrointestinal symptoms, the dosage was reduced to the last well-tolerated dosage. For example,
we decreased the dose by 250 mg/dose for one week when participants reported difficulty tolerating
study medication and then attempted to increase it.
3.2. Policaptil Gel Retard® (PGR) Treatment
As previously reported [21], PGR is the active pharmaceutical ingredient (API) of the medical
device Libramed tablets (Aboca Spa Company, Sansepolcro, Arezzo, Italy). This complex contains
polysaccharide macromolecules (cellulose, hemicellulose, pectin, and mucilage) and is derived from
the following high-fiber raw materials: glucomannan (Amorphophallus konjac), cellulose, Opuntia
pulp stem (Opuntia ficus indica), chicory root (Cichorium intybus), freeze-dried mallow root mucilage
(Althaea officinalis), freeze-dried flaxseed mucilage (Linum usitatissimum L) and freeze-dried linden
flower mucilage (Tilia platyphyllos Scop). PGR slows the rate of carbohydrate absorption, hence
potentially reducing peak blood glucose and insulin concentrations. The exact composition and
production process of the API are covered by a European patent (no. 1679009). All patients took three
tablets (2175 mg) before their two main meals.
3.3. Adherence to Study Protocol
Adherence to therapy was evaluated by means of written instructions provided at T0 and at
clinical controls through a written questionnaire completed by the parents. As per clinical practice,
adherence was also verified by e-mails and telephone interviews and by the bottle count on number
of tablets consumed performed at the programmed visits. Furthermore, adherence to the diet was
measured through the food record and 24-h recall of all food and drink intake and was revealed on the
individual consultation, when specific questioned were asked about the food record.
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3.4. Control Group
Patients with obesity and MetS, who chose not to take a medication as a mean to reduce weight
and treated only with a LGI served as a control group (51 subjects; 24 males, 27 females; median
age at study entry 12.4, range 8.2–14.5 years). For minimize the confounding effect of the LGI on
auxological and metabolic parameters, this control group was age-, sex-, and BMI-matched and had no
statistical different auxological and metabolic parameters at T0 in respect to the study group. Inclusion
and exclusion criteria and the study protocol of the control group were the same as previously seen
for patients.
3.5. Study Protocol
As reported above, at T0, T1 and T2, the habitual food intake of the patients in the six
months prior to and during the study was assessed using a validated quantitative food frequency
questionnaire [21,22]. Standardized pictures of small, medium and large food portions were used to
increase the accuracy of estimated food consumption [21].
The glycemic index (GI) of the diet of each patient was estimated from the sum of the GI values
of each food consumed daily (GIA, GIB, GIC, etc. according to the amount (in grams) of available
carbohydrate in each food (gA, gB, gC, etc.) divided by the total amount of available carbohydrate
(g), as described by Wolever et al. [23]. The GI of each food was obtained from the values published
in the International Table of Glycemic Index, considering glucose as reference [24]. For foods not
listed in this table, the GI of foods with a similar nutritional composition and preparation method was
used. GI values of the edible products were assumed as following: GI < 55 low, GI = 56–70 medium,
GI > 70 high [23].
As per clinical practice, the study’s dietician provided to ask a complete a three-day food record
(including two weekdays and two weekend days) at baseline and again three months. These four-day
food diaries provided information on dietary composition and served as the basis of individualized
dietary counseling. A 24-h recall of all food and drink intake was conducted during each session to
assess compliance. In the case of noncompliance, suitable alternative LGI foods were encouraged.
Food sample baskets containing key foods for the assigned diet were provided to promote product
recognition and dietary adherence. LGI have a target GI ≤ 55. Our eating guideline encouraged
the addition of fiber (exchanging white bread to whole meal bread) and legumes (lentil, peas, and
beans), and focused on designing meals using low-GI carbohydrate foods. Examples of LGI foods
used in this study: legumes (beans, chick pea, and lentils), whole grains (oat, barley, bulgur wheat,
cracked wheat, semolina, basmati rice, and all bran), temperate fruits (apples, berries, pears, apricot,
peach, plums, etc.), citrus fruits (oranges, grapefruit, tangerine, and pineapple), “above the ground”
vegetables (squash, mixed vegetables, green beans, broccoli, tomato juice, tomato sauce, vegetable
soups, asparagus, cauliflower, spinach, cabbage and onions, leafy greens, all above ground growing
vegetables, and carrots), breads (pumpernickel and whole grain), and cereals (muesli with whole grain
flakes, raw bran, etc).
The age of pubertal onset was defined as the age at durable Tanner B2 stage for females or a
testicular volume of 14 mL for males (G2). The age at which this occurred was taken as mid-age
between the previous clinic visit when the child was still prepubertal and the clinic visit when the
child was G2/B2. Duration of puberty was taken as time from G2/B2 to G4/B4. Age at G4/B4 was
assessed similarly by taking mid-age between the previous clinic visit when the child was G3/B3 and
the clinic visit when the child was G4/B4 [25].
Obesity was defined according to the reference values in growth charts as shown in the study by
Cacciari et al. [26]. Children with a BMI greater than the 95th percentile for their age and gender were
classified as obese.
The variables for insulin resistance and β-cell function were evaluated in all patients by OGTT,
carried out at T0, T1 and T2. OGTT was performed at four time points after an overnight fast of 12 h.
After insertion of a venous cannula and collection of the baseline blood sample (T0), participants
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ingested 1.75 g of glucose per kilogram of body weight (maximum dose 75 g), dissolved in 200–300 mL
of water. Glucose and insulin levels were determined at baseline and 30, 60, 90 and 120 min after
ingestion of the glucose solution [22].
The glycemic status was defined based on 2010 American Diabetes Association criteria [27].
Impaired fasting glucose (IFG) was defined as fasting plasma glucose (FPG) 100–125 mg/dL
(5.6–6.9 mmol/L). Impaired glucose tolerance (IGT) was defined as OGTT 2-h value 140–199 mg/dL
(7.8–11.0 mmol/L). Finally, diabetes was defined as FPG ≥ 126 mg/dL (≥ 7.0 mmol/L) and OGTT 2-h
plasma glucose ≥ 200 mg/dL (≥ 11.1 mmol/L).
The HOMA-IR and the Matsuda index of insulin sensitivity [28–30] were calculated for all patients.
A low HOMA-IR index indicates high insulin sensitivity, whereas a high HOMA-IR index indicates
low insulin sensitivity (insulin resistance). HOMA-IR > 4.4 was considered as consistent with insulin
resistance [30,31]. The Matsuda index [29] also provides a measure of insulin sensitivity and is
calculated using the following equation:
Matsuda index = 10,000/(square-root (FPG x FPI) × (meanPG x meanPI)
Where FPG is fasting plasma glucose, FPI is fasting plasma insulin, PG is plasma glucose and PI is
plasma insulin. The Matsuda index is consistent with direct measurements using an insulin clamp [29].
The glucose and insulin area under the curve (AUC) during the OGTT were calculated using the
trapezoidal rule [32]. Delta glucose (∆G30–0) and delta insulin (∆I30–0) were evaluated as the changes
in glucose and insulin concentrations from 0 min to 30 min. The insulinogenic index, calculated
as (Ins30-Ins0)/(Glu30-Glu0), was used to estimate insulin secretion [33]. The β-cell compensatory
capacity was evaluated using the disposition index (DI), defined as the product of the Matsuda and
insulinogenic indices [33].
MetS was diagnosed applying the International Diabetes Federation (IDF) 2007 definition
according to different age groups: 6 to <10, 10 to <16, and ≥16 years. For children aged 10 to <16 years,
MetS was diagnosed by the presence of abdominal obesity (WC≥ 90th percentile for age and gender)
plus two or more of the other features: elevated TG (≥1.7 mmol/L), low HDL-C (<1.03 mmol/L), high
blood pressure (BP) (systolic (SBP) ≥ 130 mmHg or diastolic (DBP) ≥ 85 mmHg) and elevated blood
glucose (≥5.6 mmol/L) [34–36]. IDF criteria for adults [36] were used to identify MetS in those aged
≥16 years. For children under 10 years, the individual risk components of MetS were defined as for
children aged 10 to <16 years [36].
3.6. Auxological and Clinical Methods
Height was measured, in triplicate, to the nearest 0.1 cm using a wall-mounted Harpenden
stadiometer in the Anna Meyer Children’s Hospital. All measurements were carried out by the same
trained staff members. The coefficient of variation (CV) for these measurements was <1%. Weight
was recorded on a digital scale to the nearest 0.05 kg, with the subject shoeless and dressed in light
underwear. BMI was calculated as body weight divided by height squared (kg/m2). Height, weight
and BMI were stratified using Italian growth charts [26]. Pubertal staging was carried out according to
Tanner and Whitehouse’s criteria, using an orchidometer for the boys [37].
Waist circumference was measured to the nearest 0.1 cm at the end of normal expiration using
a non-elastic tape measure placed midway between the lowest rib margin and the iliac crest [36,37].
Hip circumference was measured to the nearest 0.1 cm using a tape measure positioned horizontally
over the widest part of the gluteal region as the subject stood relaxed with his/her feet placed as close
together as possible [38,39]. All measurements were taken twice. The waist/hip ratio was calculated
using these measurements [40].
Height, weight, BMI, waist circumference and hip circumference were normalized for
chronological age by conversion to standard deviation scores (SDSs) [25].
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Acanthosis nigricans on the neck was assessed for severity by a validated scale ranging from
grade 0 (not present) to grade 4 (severe: extending anteriorly, visible when the participant is viewed
from the front) [41].
Blood pressure was measured three times by trained personnel by auscultation using a mercury
sphygmomanometer on the right arm after the patient had been sitting quietly for 5 min, with
the back supported, feet on the floor, right arm supported and cubital fossa at heart level [42].
An appropriate cuff size was used and the 5th Korotkoff sound was taken for diastolic blood pressure
categorization. The mean systolic and diastolic values were recorded and stratified according to the
pediatric percentiles of the National High Blood Pressure Education Program Working Group on
High Blood Pressure in Children and Adolescents [42]. The mean value of the three measurements
was also converted into SDS to enable some of the statistical analyses [42].
3.7. Laboratory Methods
All participants were examined in the morning after an overnight fast. Blood samples were
collected by venepuncture or, for OGTT, by venous cannula, during scheduled hospital visits.
After collection, serum and plasma were immediately separated and stored at −20 ◦C in multiple vials
for later analysis. All samples were collected by research staff and analyzed in the clinical laboratory
of the Anna Meyer Children’s University Hospital.
Serum glucose (Dimension RXL system, Dade Behring, Dallas, TX, USA) and serum insulin
(IMMULITE 2000 analyzer, Siemens Healthcare Diagnostics, Marburg, Germany) levels were measured
using immunoenzymatic assays and glycosylated haemoglobin (HbA1c) levels were determined using
high performance liquid chromatography (DIAMAT, Bio-Rad, Richmond, CA, USA). The normal range
for HbA1c was 4.2%–6.0%, and the coefficient of variation (CV) at 5.5% was 4.8.
Total cholesterol, HDL cholesterol, and triglyceride (TG) were measured using routine laboratory
methods. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedwald formula:
LDL = total cholesterol−HDL cholesterol−TG/2.2 [30].
4. Statistical Analysis
Data were analyzed using IBM SPSS Statistics software version 22 (IBM, Armonk, NY, USA).
Baseline data are reported as descriptive statistics. Normally distributed data are reported as mean
± SD, and nonparametric data as median (range). To assess the effect of PGR plus metformin versus
metformin alone, Student’s T test was used to compare the means of normally distributed data and
the Mann–Whitney U test to compare nonparametric data. The χ2 test or Fisher's exact test, when
appropriate, was used for dichotomous outcomes (progression of impaired fasting glucose, impaired
glucose tolerance and T2DM). General linear models (analysis of repeated measure (analysis of variance
or ANOVA)) or mixed models (in cases of too many missing data) were used to determine the effects
of each type of treatment on different time points to baseline. Tukey honest significance difference test
was used for post hoc multiple comparisons. Differences with p < 0.05 were considered significant.
5. Results
The primary demographic, clinical and laboratory characteristics of patients and controls are
summarized in Tables 1 and 2. All baseline characteristics were similar for both males and females
(Table 1), and there were not significantly more girls than boys in puberty (Tanner stage 2–5). A family
history of MetS in either first or second degree relatives was found for 99 patients (76.7%), without
significant difference with the controls (41 patients, 80.4%).
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Table 1. Anthropometric, dietary, clinical and biochemical features before and after metformin
treatment and in control group.
Features T0 (Patients) T0 (Controls) T1 (Patients) T1 (Controls)
Age, years 12.6 (8.1–14.3) 12.4 (8.2–14.5) 13.7 (9.1–15.4) 13.6 (9.2–15.5)
Tanner stage
Prepubertal/pubertal, n (%) 66/63 (51.2/48.8) 27/24 (52.9/47.1) 56/73 (43.4/56.6) 22/29 (43.1/56.9)
Height, SDS 0.55 ± 0.96 0.53 ± 0.91 0.50 ± 0.93 0.56 ± 0.88
BMI, SDS 2.44 ± 0.25 2.42 ± 0.26 2.18 ± 0.21 *** 2.31 ± 0.24 *,††
Waist, SDS 3.14 ± 0.63 3.12 ± 0.66 2.78 ± 0.52 *** 2.99 ± 0.61 †
Hip SDS 4.08 ± 0.72 4.10 ± 0.70 3.73 ± 0.65 *** 4.01 ± 0.71 †
WHR 0.88 ± 0.05 0.89 ± 0.06 0.87 ± 0.02 * 0.88 ± 0.05
Acanthosis nigricans, % 76 (58.9%) 27 (52.9%) 53 (41.1%) ** 28 (54.9%) ††
Glycemic Index 59.3 ±15.5 58.9 ±16.2 47.6 ± 7.3 *** 47.7 ± 7.2 ***
Energy intake, kcal 2,206 ± 458 2,181 ± 443 2,008 ± 364 ** 1,975 ± 386 *
Fiber consumption, g 16.5 ± 7.8 16.0 ± 7.2 20.8 ± 9.4 *** 21.5 ± 9.6 **
Fat consumption, g 77.7 ± 20.2 74.9 ± 19.7 62.8 ± 20.3 *** 61.7 ± 23.4 ***
Carbohydrate consumption, g 299.0 ± 64.4 297.0 ± 69.1 286.0 ± 75.9 *** 286.5 ± 70.4 **
Protein consumption, g 94.6 ± 19.9 96.5 ± 22.3 89.8 ± 20.7 91.4 ± 23.1
HOMA-IR 7.42 ± 1.94 6.99 ± 1.81 6.11 ± 1.23 *** 6.23 ± 1.94 *
ISOGTT, SDS 1.22 ± 0.29 1.31 ± 0.27 1.51 ± 0.22 *** 1.42 ± 0.24 *,†
Insulinogenic index 3.78 ± 2.81 3.63 ± 2.70 2.95 ± 1.96 * 3.51 ± 2.04
Disposition index 4.73 ± 3.84 4.12 ± 3.71 4.53 ± 3.38 4.43 ± 3.74
Glucose post-OGTT (120 min),
mg/dL 129.85 ± 28.27 132.62 ± 26.94 115.57 ± 24.16 *** 127.89 ± 23.77
HbA1C, % 6.29 ± 0.31 6.19 ± 0.32 6.01 ± 0.35 *** 6.03 ± 0.28 *
Systolic BP, SDS 1.53 ± 0.92 1.56 ± 0.99 1.45 ± 0.90 1.52 ± 0.90
Diastolic BP, SDS 1.56 ± 0.78 1.61 ± 0.84 1.35 ± 0.83 * 1.55 ± 0.73
Glucose metabolism abnormalities, n (%)
IFG 49 (38.0%) 16 (31.4%) 28 (21.7%) *** 15 (29.4%)
IGT 31 (24.3%) 12 (23.5%) 21 (16.3%) * 11 (21.6%)
T2DM 6 (4.6%) 2 (3.9%) 5 (3.9%) 2 (3.9%)
Triglyceride, mmol/L 1.77 ± 0.31 1.88 ± 0.40 1.82 ± 0.33 1.75 ± 0.36
Total cholesterol, mmol/L 5.82 ± 0.61 5.74 ± 0.73 5.71 ± 0.62 5.56 ± 0.64
HDL-cholesterol, mmol/L 0.81 ± 0.14 0.83 ± 0.13 0.88 ± 0.14 *** 0.85 ± 0.15
LDL-cholesterol, mmol/L 4.20 ± 0.65 4.04 ± 0.59 3.98 ± 0.68 * 3.90 ± 0.57
ALT, U/L 57.23 ± 20.89 53.67 ± 18.91 52.32 ± 20.24 51.45 ± 17.76
AST, U/L 59.66 ± 27.53 55.21 ± 24.90 53.76 ± 23.19 53.45 ± 22.84
SDS, standard deviation score; BMI, body mass index; WHR, waist-hip ratio; HOMA-IR, homeostasis model of
assessment for insulin-resistance; ISOGTT, Matsuda index; BP, blood pressure; IFG, impaired fasting glucose; IGT,
impaired glucose tolerance; T2DM, type 2 diabetes mellitus. T0 patients vs. T1 patients: * p < 0.05; *** p < 0.0001.
T0 controls vs. T1 controls: * p < 0.05; *** p < 0.0001. T1 patients vs. T1 controls: † p < 0.05; †† p < 0.005.
Table 2. Anthropometric, clinical and biochemical differences during treatment with metformin or

















Age, yrs 13.7 (9.1–15.3) 13.8 (9.2–15.4) 13.6 (9.2–15.5) 14.8 (10.2–16.3) 14.8 (10.1–16.5) 14.6 (10.2–16.5)
Tanner stage











Height, SDS 0.48 ± 0.88 0.52 ± 0.97 0.56 ± 0.88 0.48 ± 0.91 0.51 ± 0.96 0.54 ± 0.91
BMI, SDS 2.22 ± 0.20 † 2.20 ± 0.22† 2.31 ± 0.24 1.92 ± 0.17 ***,††† 2.14 ± 0.20 ††,‡‡‡ 2.28 ± 0.26
Waist, SDS 2.75 ± 0.58 † 2.82 ± 0.45 2.99 ± 0.61 2.42 ± 0.43 **,††† 2.75 ± 0.43 †,‡‡‡ 2.96 ± 0.57
Hip SDS 3.78 ± 0.69 3.68 ± 0.62 † 4.01 ± 0.71 3.30 ± 0.41 ***,††† 3.47 ± 0.57 † 3.79 ± 0.79
WHR 0.87 ± 0.02 0.87 ± 0.03 0.88 ± 0.05 0.87 ± 0.02 0.87 ± 0.03 0.88 ± 0.03
Acanthosis nigricans, % 28 (39.4%) †† 25 (43.1%) † 28 (54.9%) 20 (15.5%) ***,††† 21 (36.2%) ††,‡‡‡ 27 (52.9%)
Glycemic Index 47.2 ± 7.1 47.8 ± 7.5 47.7 ± 7.2 46.9 ± 7.0 47.4 ± 6.8 48.3 ± 6.6
Energy intake, kcal 1989 ± 345 2,024 ± 389 1,975 ± 386 1,982 ± 357 1,993 ± 371 1,967 ± 381
Fiber consumption, g 20.1 ± 9.7 21.5 ± 9.0 21.5 ± 9.6 22.6 ± 9.0 23.6 ± 9.9 23.0 ± 9.8
Fat consumption, g 60.1 ± 19.3 64.9 ± 21.5 61.7 ± 23.4 63.1 ± 22.3 62.7 ± 24.2 61.1 ± 23.8
Carbohydrate consumption, g 271.8 ± 78.9 298.1 ± 72.3 286.5 ± 70.4 284.3 ± 78.0 288.0 ± 75.1 286.4 ± 68.9
Protein consumption, g 90.6 ± 18.6 87.7 ± 23.5 91.4 ± 23.1 89.8 ± 20.4 91.0 ± 22.9 90.9 ± 24.7
HOMA-IR 6.31 ± 1.31 5.89 ± 1.14 6.23 ± 1.94 4.12 ± 0.47 ***,††† 5.97 ± 1.11 ‡‡‡ 6.56 ± 2.17
ISOGTT, SDS 1.47 ± 0.19 1.53 ± 0.25† 1.42 ± 0.24 2.27 ± 0.52 ***,††† 1.65 ± 0.21 *,‡‡‡ 1.59 ± 0.38
Insulinogenic index 2.81 ± 1.69 † 3.18 ± 2.29 3.51 ± 2.04 2.24 ± 1.12 *,††† 2.97 ± 1.98 ‡ 3.67 ± 2.36
Disposition index 4.27 ± 2.81 4.79 ± 3.96 4.43 ± 3.74 6.78 ± 2.99 ***,†† 4.92 ± 2.56 ‡‡ 4.78 ± 3.34
Glucose post-OGTT
(120 min), mg/dL 115.78 ± 22.69
† 119.23 ± 26.57 127.89 ± 23.77 98.87 ± 24.78 ***,†† 106.70 ± 25.65 118.31 ± 26.33
HbA1C, % 5.98 ± 0.41 6.04 ± 0.29 6.03 ± 0.28 5.71 ± 0.28 ***,††† 5.94 ± 0.26 ‡‡‡ 6.03 ± 0.28
Systolic BP, SDS 1.49 ± 0.73 1.41 ± 1.08 1.52 ± 0.90 1.21 ± 0.82 * 1.33 ± 1.08 1.52 ± 0.90
Diastolic BP, SDS 1.38 ± 0.86 1.33 ± 0.82 1.55 ± 0.73 1.25 ± 0.79 † 1.30 ± 0.83 1.55 ± 0.73


















Glucose metabolism abnormalities, n (%)
IFG 15 (21.1%) 13 (22.4%) 15 (29.4%) 5 (7.0%) ***,††† 9 (15.5%) ††† 14 (27.5%)
IGT 11 (15.5%) 10 (17.2%) 11 (21.6%) 5 (7.0%) *,††† 7 (12.1%) 10 (19.6%)
T2DM 3 (4.2%) 2 (3.4%) 2 (3.9%) 1 (1.4%) **,††† 1 (1.7%) †† 3 (5.9%)
Triglyceride, mmol/L 1.77 ± 0.27 1.87 ± 0.37 1.75 ± 0.36 1.58 ± 0.15 *** 1.57 ± 0.15 *** 1.68 ± 0.43
Total cholesterol, mmol/L 5.80 ± 0.58 5.63 ± 0.66 5.56 ± 0.64 5.18 ± 0.68 ***,† 5.52 ± 0.65 ‡‡ 5.50 ± 0.71
HDL-cholesterol, mmol/L 0.91 ± 0.14 † 0.86 ± 0.14 0.85 ± 0.15 1.06 ± 0.11 ***,††† 0.92 ± 0.15 †,‡‡‡ 0.84 ± 0.19
LDL-cholesterol, mmol/L 4.05 ± 0.65 3.82 ± 1.06 3.94 ± 0.57 3.25 ± 0.90 ***,††† 3.86 ± 0.68 ‡‡‡ 3.90 ± 0.51
ALT, U/L 56.20 ± 20.45 48.50 ± 19.90 51.45 ± 17.76 40.02 ± 13.27 ***,††† 48.26 ± 14.98 ‡ 52.89 ± 19.63
AST, U/L 57.85 ± 24.90 49.00 ± 22.15 53.45 ± 22.84 42.00 ± 17.10 ***,†† 48.55 ± 16.53 55.67 ± 24.39
SDS, standard deviation score; BMI, body mass index; WHR, waist hip ratio; HOMA-IR, homeostasis model of
assessment for insulin-resistance; ISOGTT, Matsuda index; BP, blood pressure; IFG, impaired fasting glucose; IGT,
impaired glucose tolerance; T2DM, type 2 diabetes mellitus; * p < 0.05; ** p < 0.005; *** p < 0.0001. T1 (Group A
and/or B) patients vs. T2 (Group A and/or B) patients and T1 vs. T2 controls: * p < 0.05; ** p < 0.005 *** p < 0.0001.
T1 (Group A and/or B) patients vs. T1 controls and T2 (Group A and/or B) patients vs. T2 controls: † p < 0.05;
†† p < 0.005; ††† p < 0.0001. T1 Group A patients vs. T1 group B patients and T2 group A patients vs. T2 groups B
patients: ‡ p < 0.05; ‡‡ p < 0.005; ‡‡‡ p < 0.001.
5.1. Metformin Intervention
At the onset of metformin treatment (T0) 66 patients were prepubertal and 63 were pubertal
(28 in Tanner stage 2 and 35 in stages 3–5), without significant difference in respect to the controls
(27 prepubertal, 10 in Tanner 2 and 14 in stages 3–5).
Regarding SDSs, we did not discover significant differences between patients and controls
(Table 1). Furthermore, both patients and controls showed a significant imbalance of energy intake
with a high-protein, high-fat, high-sugar carbohydrate and poor-fiber diet than expected in Italian
non-obese peers [43]. However, at T0 we not discovered significant difference in relation to the mean
GI, energy intake, consumption of fiber, fat, carbohydrate and protein in patients and controls (Table 1).
Seventy-six patients (58.9%) presented acanthosis nigricans (controls: 27 patients, 52.9%). All
patients and controls had MetS: waist SDS was > 2 in all patients and controls; 49/129 (38.0%) patients
and 16/51 (31.4%) controls presented impaired fasting glucose; 53/129 (41.1%) patients and 25/51
(49.0%) controls presented elevated TG, 113/129 (87.6%) patients and 41/51 (80.4%) controls presented
reduced HDL cholesterol levels, 68/129 (52.7%) patients and 29/51 (56.9%) controls presented elevated
SBP and 56/129 (43.4%) patients and 27/51 (47.1%) controls presented elevated DBP.
At T0 glucose-insulinemic metabolism and metabolic parameters did not show statistically
significant differences between patients and controls: HOMA-IR 7.42 ± 1.94 (controls: 6.99 ± 1.81),
Matsuda index 1.22 ± 0.29 (controls: 1.31 ± 0.27), disposition index 4.73 ± 3.84 (controls:
4.12 ± 3.71), insulinogenic index 3.78 ± 2.81 (controls: 3.63 ± 2.70), HbA1c 6.29 ± 0.31% (controls:
6.19 ± 0.32%), total cholesterol 5.82 ± 0.61 mmol/L (controls: 5,74 ± 0.73 mmol/L), HDL cholesterol
0.81 ± 0.14 mmol/L (controls: 0.83 ± 0.13 mmol/L), LDL cholesterol 4.20 ± 0.65 mmol/L (controls:
4.12 ± 0.59 mmol/L), triglycerides 1.77 ± 0.31 mmol/L (controls: 1.93 ± 0.40 mmol/L), ALT
57.23 ± 20.89 U/L (controls: 53.67 ± 18.91 U/L), AST 59.66 ± 27.53 U/L (controls: 55.21 ± 24.90), SBP
SDS 1.53 ± 0.92 (controls: 1.56 ± 0.99), DBS SDS 1.56 ± 0.78 (controls: 1.61 ± 0.84) (Table 1).
As expected, we did show statistically significant differences between prepubertal and pubertal
subjects both in patients and controls regarding HOMA-IR, Matsuda index, disposition index,
insulinogenic index and HbA1c levels. However, the comparison of prepubertal patients and controls
groups and pubertal patients and controls groups did not allow showing significant differences
between the groups relatively to the examined parameters (data not shown).
After 12 months of metformin treatment (T1), there was no significant difference in height SDS
in patients (0.50 ± 0.93 vs. 0.55 ± 0.96) and controls (0.56 ± 0.88 vs. 0.53 ± 0.91), whereas there was
a significant reduction in BMI SDS in patients (2.18 ± 0.21 vs. 2.44 ± 0.25, p < 0.0001) and controls
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(2.31 ± 0.24 vs. 2.42 ± 0.26, p < 0.05), with a significant difference in ∆BMI SDS between patients and
controls (−0.26 ± 0.04 vs. −0.11 ± 0.02, p < 0.0001), revealing that metformin has a significant effect on
weight reduction (Table 1). Moreover, patients treated with metformin disclosed significant differences
regarding to waist SDS (2.78 ± 0.52 vs. 3.14 ± 0.63; p < 0.0001), hip SDS (3.73 ± 0.65 vs. 4.08 ± 0.72;
p < 0.0001) and WHR (0.88 ± 0.05 vs. 0.87 ± 0.02; p < 0.05). On the contrary, patients treated with
LGI no showed a significant reduction in waist SDS (2.99 ± 0.61 vs. 3.12 ± 0.66), hip SDS (4.01 ± 0.71
vs. 4.10 ± 0.70) and WHR SDS (0.88 ± 0.05 vs. 0.89 ± 0.06). Furthermore, patients and controls had
significant differences with regard to ∆waist SDS (−0.36 ± 0.11 vs. 0.13 ± 0.05; p < 0.0001), ∆hip SDS
(−0.35 ± 0.07 vs. −0.09 ± 0.01; p < 0.0001), but no ∆WHR SDS (−0.01 ± 0.03 vs. −0.01 ± 0.01). These
differences were not significative comparins prepubertal and pubertal patients and controls.
Twenty-one patients (41.1%) presented acanthosis nigricans, a significant reduction from T0
(p < 0.0005), with significant difference in respect to the control group (54.9%; p < 0.005). Furthermore,
there was also a significant reduction in patients in HOMA-IR (6.11 ± 1.23 vs. 7.42 ± 1.94; p < 0.0001)
and insulinogenic index (2.95 ± 1.96 vs. 3.78 ± 2.81; p < 0.05), and a significant increase in Matsuda
index (1.51 ± 0.22 vs. 1.22 ± 0.29; p < 0.0001). There was no significant difference in disposition index
from T0 (4.53 ± 3.38 vs. 4.73 ± 3.84). On the contrary, controls showed a significant reduction in
HOMA-IR (6.23 ± 1.94 vs. 6.99 ± 1.81; p < 0.05) and a significant increase in Matsuda index (1.42 ± 0.24
vs. 1.31 ± 0.27; p < 0.05), whereas insulinogenic index (3.51 ± 2.04 vs. 3.63 ± 2.70) and disposition index
(4.43 ± 3.74 vs. 4.12 ± 3.71) did not showed significant differences. Finally, HbA1c was significantly
reduced in patients (6.01 ± 0.35 vs. 6.29 ± 0.31; p < 0.0001) and controls (6.03 ± 0.28% vs. 6.19 ± 0.32%;
p < 0.05), whereas HDL cholesterol (0.88 ± 0.14 vs. 0.81 ± 0.14 mmol/L; p < 0.0001) was significantly
increased and LDL cholesterol (3.98 ± 0.68 vs. 4.20 ± 0.65 mmol/L; p < 0.05) decreased in patients.
Nevertheless, both in patients than in controls, there were no significant differences in total
cholesterol, triglycerides, ALT, AST, SBP SDS or DBS SDS (Table 1). Finally, all patients still presented
MetS: waist SDS > 2 in all patients; impaired fasting glucose in 28/129 (21.7% vs. 38.0% at T0;
p < 0.0001); elevated TG in 68/129 (52.7% vs. 41.1% at T0; p < 0.05), reduced HDL cholesterol in
111/129 (86.0% vs. 87.6% at T0; p = NS), elevated SBP in 59/129 (45.7% vs. 52.7% at T0; p = NS) and
elevated DBP in 41/129 (31.7% vs. 43.4% at T0; p < 0.005). On the contrary, in controls impaired fasting
glucose was discovered in 29.4% (vs. 31.4% at T0; p = NS), elevated TG in 68.6% (vs. 80.4% at T0;
p < 0.05), reduced HDL cholesterol in 76.5% (vs. 80.4% at T0; p = NS), elevated SBP in 52.9% (vs. 56.9%
at T0; p = NS) and elevated DBP in 43.1% (vs. 47.1% at T0; p < 0.005).
However, after 12 months of metformin treatment, we did show statistically significant differences
between prepubertal and pubertal patients in respect to respective subjects of the control group and
between prepubertal and pubertal subjects of the control group, but not between prepubertal and
pubertal patients, relatively to HOMA-IR, Matsuda index, disposition index, insulinogenic index and
HbA1c levels (data not shown).
The result of the dietary analysis after the 6-week of LGI diet showed a slight change in caloric
intake both in patients (2008 ± 364 Kcal vs. 2,206 ± 458 Kcal; p < 0.005) and in controls (1975 ± 386
vs. 2,181 ± 443 kcal; p < 0.05), without significant differences between the two groups. Furthermore,
at T1, the mean GI was also significantly reduced in patients (47.6 ± 7.3 vs. 59.3 ± 15.5; p < 0.0001)
and controls (47.7 ± 7.2 vs. 58.9 ± 16.2; p < 0.0001). Furthermore, there were favorable not significant
changes in some macronutrient intakes: protein intake increased (patients: 89.8 ± 20.7 vs. 94.6 ± 19.9 g;
controls: 91.4 ± 23.1 vs. 96.5 ± 22.3) and carbohydrate intake decreased (Patients: 286.0 ± 75.9 g vs.
299 ± 64.4 g; controls: 286.5 ± 70.4 g vs. 297.0 ± 69.1 g), even if with significant differences between
complex and simple carbohydrates, as demonstrated by the significant reduction in the glycemic
index. However, fat intake significantly decreased (patients: 62.8 ± 20.3 vs 77.7 ± 20.2 g, p < 0.0001;
controls: 61.7 ± 23.4 g vs. 74.9 ± 19.7 g, p < 0.0001) and fiber intake increased (patients: 20.8 ± 9.4 g vs.
16.5 ± 7.8 g, p < 0.0001; controls: 21.5 ± 9.6 vs. 16.0 ± 7.2 g, p < 0.005) (Table 1).
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5.2. Metformin Plus Policaptil Gel® Retard Versus Metformin Alone
At T1, after dividing the patients into groups A (metformin plus PGR) and B (metformin only),
there were no significant differences in metformin treatment doses between the group A and B
and between prepubertal and pubertal patients (data not shown), physical activity scores (data not
shown), LGI diet characteristics (Table 2). Furthermore, we did not disclosed significant differences in
male/female ratio and prepubertal/pubertal ratio among the two groups of patients and the controls
(Table 2). Moreover, there were no significant differences in height SDS waist SDS, WHR, HOMA-IR,
insulinogenic index, disposition index, HbA1c, total cholesterol, LDL cholesterol, triglycerides, ALT,
AST, SBP SDS or DBP SDS among the two groups of patients and the controls, whereas patients
showed significant differences in BMI SDS (F: 3.890; p < 0.05), hip SDS (F: 3.391; p < 0.05), Matsuda
index (F: 3.271; p < 0.05), and HDL-cholesterol (F: 3.720; p < 0.05) among the two groups of patients
and the controls (Table 2).
At T2, the mean GI was 46.9 ± 7.0 for the for the group A, 47.4 ± 6.8 for the group B and 48.3 ± 6.6
for the controls, without significant differences among the groups, as well as regarding energy intakes,
consumed fiber, fat, carbohydrate or protein intake (Table 2). Moreover, also the result of the dietary
analysis at T2 showed no change in GI, caloric intake and macronutrient intake in respect to T1 both in
patients and in controls (Table 2).
The comparison at T2 among the three groups disclosed significant differences regarding BMI SDS
(F: 46.496; p < 0.0001), waist SDS (F: 20.232; p < 0.0001) and hip SDS (F: 10.325; p < 0.0001). In particular,
group A of patients showed BMI SDS and waist SDS values significantly reduced in comparison to
group B and the controls (p < 0.0001), whereas hip SDS value was significantly reduced in respect to
the controls only (p < 0.001). Moreover, group B also disclosed reduced values of BMI SDS (p < 0.005),
waist SDS (p < 0.05) and hip SDS (p < 0.05) in respect to the controls (Table 2).
In comparison to T1, at T2 Group A (PGR plus metformin) presented a significant reduction in
BMI SDS (1.92 ± 0.17 vs. 2.22 ± 0.20; p < 0.0001), waist SDS (2.42 ± 0.43 vs. 2.75 ± 0.58; p < 0.0005) and
hip SDS (3.30 ± 0.41 vs. 3.78 ± 0.69; p < 0.0001), whereas in Group B (metformin alone) and controls
there was no further statistically significant differences with respect to T1.
Group A and B showed also a significant reduction of patients with acanthosis nigricans
(respectively, p < 0.0001 and p < 0.005) in comparison to controls at T2; however, in group A this
reduction was significantly different also in respect to group B (p < 0.0001), and in comparison to T1
(p < 0.0001) (Table 2).
The T2 comparison among the groups A and B and the controls disclosed significant differences
regarding HOMA-IR (F: 56.160; p < 0.0001), Matsuda (F: 56.059; p < 0.0001), insulinogenic (F: 9.211;
p < 0.0001) and disposition (F: 9.090; p < 0.0001) indexes. In particular, group A of patients showed
significant differences in HOMA-IR (p < 0.0001), Matsuda index (p < 0.0001), disposition index
(p < 0.005) and insulinogenic index (respectively, p < 0.05 and p < 0.0001) in respect to the group
B and controls.
Moreover, in comparison to T1, at T2 in both Groups A and B there was a significant increase in
insulin sensitivity (A: 2.27 ± 0.52 vs. 1.47 ± 0.19; p < 0.0001; B: 1.65 ± 0.21 vs. 1.53 ± 0.25; p < 0.05).
In Group A there was also a significant reduction in HOMA-IR (4.12 ± 0.47 vs. 6.31 ± 1.31, p < 0.0001)
and a significant increase in disposition (6.78 ± 2.99 vs. 4.27 ± 2.81, p < 0.0001) and insulinogenic
(2.24 ± 1.12 vs. 2.81 ± 1.69, p < 0.05) indices. However, Matsuda index was also significantly increased
in group B in respect to T1 (p < 0.05). In contrast, there was no further significant difference in these
parameters in the controls.
At T2, the comparison among the groups A and B and the controls disclosed significant differences
in HbA1c levels (F: 22.712; p < 0.0001), total cholesterol (F: 5.060; p = 0.0007), HDL cholesterol (F: 34.352;
p < 0.0001), LDL cholesterol (F: 15.697; p < 0.0001), ALT (F: 14.434; p < 0.0001) and AST (F: 7.498;
p = 0.0001). In particular, group A disclosed significant reduced HbA1c levels (p < 0.0001), total
cholesterol (respectively, p < 0.005 and p < 0.05), HDL cholesterol (p < 0.0001), LDL cholesterol
(p < 0.0001) and ALT (respectively, p < 0.05 and p < 0.0001) in comparison to group B and controls.
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Moreover group A showed a significant reduction also of AST in respect to controls (p < 0.005).
However, group B disclosed a significant increase in HDL cholesterol than controls (p < 0.05).
In comparison with Group B, Group A showed a further reduction in HbA1c levels (A: T2
5.71 ± 0.28 vs. T1 5.98 ± 0.41; p < 0.0001; B: T2 5.94 ± 0.26 vs. T1 6.04 ± 0.29). Group A also showed
a further reduction in total cholesterol (T2 5.18 ± 0.68 vs. T1 5.80 ± 0.58 mmol/L; p < 0.0001), LDL
cholesterol (T2 3.25 ± 0.90 vs. T1 4.09 ± 0.63 mmol/L; p < 0.0001) and triglycerides (T2 1.58 ± 0.15
vs. T1 1.78 ± 0.27 mmol/L; p < 0.0001) and an increase in HDL cholesterol (T2 1.06 ± 0.11 vs.
T1 0.91 ± 0.14 mmol/L; p < 0.0001) (Table 2). In contrast, Group B presented a significant further
reduction in triglycerides alone (T2 1.57 ± 0.15 vs. T1 1.88 ± 0.37 mmol/L; p < 0.0001). In contrast,
there was no further significant difference in these parameters in the controls.
At T2 group A showed a significant reduction of glucose metabolism abnormalities: patients with
IFG were significantly reduced in comparison to controls (group A: p < 0.0001; group B: p < 0.005)
and significantly reduced in comparison to T1 in group A (p < 0.0001). However, at T2 patients with
IGT or T2DM were significantly reduced, respectively, in group A (p < 0.0001) and groups A and B
(respectively, p < 0.0001 and p < 0.005) in comparison to controls, even if only group A disclosed a
significant reduction in respect to T1 (respectively, p < 0.05 and p < 0.005) (Table 2).
Finally, Group A showed a significant reduction in MetS in comparison with Group B (56% vs.
20%; p < 0.0001) and controls (group A: 56% vs. 5.8%; p < 0.0001. Group B: 20% vs. 5.8%; p = 0.005).
5.3. Safety Data and Adherence to Therapy
During the 12 months of metformin treatment (T0–T1), the incidence of adverse events was 20.1%
(27 patients); in eight patients the dosage was reduced to 500 mg twice daily, resulting in a significant
reduction in symptoms. These events included hypoglycemia (3 patients; 2.3%) diarrhea (8; 6.2%),
constipation (3; 2.3%), flatulence (6; 4.6%) and abdominal pain (9; 7.0%). No patient needed to stop the
metformin treatment and none suffered from severe gastrointestinal adverse events.
After division into treatment subgroups (from T1 to T2), metformin was well tolerated by most
patients in both Groups A (metformin + PGR) and B (metformin monotherapy). In Group A, twelve
patients (16.9%) reported adverse effects such as hypoglycemia episodes (2 patients; 2.8%), diarrhea
(4; 5.6%), flatulence (2; 2.8%) and abdominal pain (4; 5.6%). Notably, three of these had also reported
symptoms in the T0–T1 period. In Group B, ten patients (17.2%) continued to report moderate
symptoms such as diarrhea (3; 5.2%), flatulence (2; 3.4%) and abdominal pain (5; 8.6%).
Finally, based on pills or tablets counts, written instructions and questionnaires, as well as e-mails
and telephone interviews, adherence to metformin therapy was 89% (range 77%–98%), without
significantly difference in group A and B. However, the adherence to PGR treatment was 91%
(range 83%–99%).
6. Discussion
Our data show that metformin significantly reduces BMI SDS, waist circumference SDS and hip
circumference SDS in the short term, revealing a meaningful effect in children and adolescents with
obesity. It also seems to improve glucose-insulin metabolism in these patients, significantly reducing
HOMA-IR and HbA1c levels and increasing insulin sensitivity as evaluated by the Matsuda index.
This confirms previous studies in which metformin produced modest but favorable short term
effects on body weight, body composition and glucose homeostasis in obese children both with
and without insulin resistance [44–50]. Other authors have reported that metformin also provides a
statistically significant (albeit very modest) reduction in BMI when combined with lifestyle changes in
the short term [51]. While results from long term follow-up are very rare [52,53], they seem to show
a reduction in the effects of metformin on metabolic and adiposity parameters [53], strengthening
our results.
However, our data from this long-term retrospective study with 24 months of follow-up show
that, after an initial improvement, metformin alone produces no further statistically significant
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improvements in auxological and metabolic parameters. Treatment with metformin alone thus may
not be sufficient to resolve metabolic syndrome in many obese children and adolescents.
Given the prevalence of metabolic syndrome and diabetes in young adults who were obese as
children or adolescents, the exploration of conventional and pharmacological strategies to improve
insulin sensitivity is imperative. Efforts to preserve β-cell function before significant loss occurs thus
appear to be necessary in the treatment of obese youths with metabolic syndrome, possibly through
alternative treatment programs combining metformin with other products so as to maintain good
results in the long term.
Our data suggest that PGR may significantly potentiate and extend the metabolic effects of
metformin in obese children and adolescents with severe insulin resistance and metabolic syndrome.
This may be of great interest in relation to the rise in comorbidities of childhood obesity, that necessitate
new therapeutic approaches to reduce or prevent these complications, particularly in relation to
glucose-insulin metabolism. In fact, progression to IGT in adults is characterized by insulin resistance
and the inability of the β-cells to adequately compensate for high blood glucose levels through
increased insulin secretion [54]. This progression is probably also seen in children and adolescents [55].
However, although the transition from normoglycemia to IGT and subsequently to diabetes in adults
is usually a gradual phenomenon that occurs over 5–10 years, the early onset of T2DM in the young
suggests an accelerated process with shortening of the transition time between these steps [56].
However, we cannot exclude that the effect shown by metformin or by the association of
metformin plus PGR in patients with obesity and MetS may be, at least in part, due to other mechanisms,
such as changes in the gut microbiota. Interestingly, metformin treatment may improved the glycemic
profile modifying gut microbiota, and accumulating evidence suggests that the gut microbiota is an
important factor in mediating the development of obesity-related metabolic disorders, including type 2
diabetes [57,58]. For example, high-fat diet (HFD)-fed C57BL/6 mice treated with metformin showed
a higher abundance of the mucin-degrading bacterium Akkermansia muciniphila with an increase
of the number of mucin-producing goblet cells due to metformin treatment [59–61]. Other studies
in animal models disclosed an increase of Clostridium cocleatum [60], Butyrivibrio, Bifidobacterium
bifidum, and Megasphaera [61]. Similar data are hypothesized in human with T2DM [62]. Moreover,
we have no data on the possible effects of PGR on the gut microbiota. However, future studies in this
field will be needed to better understand the metabolic effects of metformin, or products such as PGR
in patients with obesity, impaired glucose metabolism and MetS. However, there is increasing interest
in utilizing dietary fibers or carbohydrate polymers in the modulation of gut microbiota [63].
Moreover, we previously showed that the PGR complex is useful in improving BMI,
metabolic parameters and glucose-insulin metabolism in obese children and adolescents with severe
hyperinsulinism and insulin resistance [21]. The present study confirms these results and shows that
PGR may be a useful natural tool, in combination with metformin, to achieve an additional reduction
in BMI, glucose-insulin and adiposity parameters, reducing the number of patients with MetS to a
significantly greater extent than metformin alone. These results highlight interesting new potential
effects of this complex.
Further studies are needed to better evaluate the pharmacokinetics of this association, in particular
studying the effect of metformin with PGR from the beginning of the treatment, for better evaluate if
its metabolic effect may be more pronounced and stable later. The effect of PGR seems to be related
to a reduction in post-meal blood glucose and insulin peaks due to slower glucose absorption, thus
attenuating pancreatic insulin response. This may potentiate the effect of metformin and achieve a
further decrease in hepatic glucose production, fasting plasma glucose, serum triacylglycerol and
VLDL and LDL levels as well as reduce C reactive protein [64].
The main limitation of this study is its open-label, retrospective design. This may cause a bias,
as participants receiving long-term metformin treatment alone, i.e. those remaining insulin resistant
and obese, may be less motivated than those receiving an adjunctive treatment. This could lead to
an overestimation of the efficacy of the association between PGR and metformin. Nevertheless,
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the same compliance seen with the different treatments suggests that this is not a major factor.
The open label construction did not influence the evaluation of adverse reactions to the different
treatments, making it possible to draw firm conclusions about the long-term safety and tolerability
of metformin and the safety and tolerability of the combination therapy. However, future research
should focus on conducting trials with sufficient power and follow-up to confirm the long-term effects
of this combination.
Another limitation of this study is the absence of a placebo group, which can be explained in
retrospective design of the study. Further prospective studies should include a placebo group not on
LGI diet to better evaluate the effect of the polysaccharide complex in improving the metabolism.
In conclusion, metformin shows short-term efficacy in reducing BMI and adiposity parameters,
which is significant in obese children and adolescents with metabolic syndrome. However, further
improvements in the long term appear more problematic. In the same population, PGR in combination
with metformin seems to potentiate the weight reduction and improve glucose-insulin metabolism
and adiposity parameters, significantly reducing the number of patients with MetS. Additional studies
that include larger sample sizes and longer longitudinal follow-up times should be performed in order
to confirm our results.
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